BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 11957790)

  • 41. Primary biliary cirrhosis and bile acids.
    Corpechot C
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis.
    Zein CO; Lindor KD
    Curr Gastroenterol Rep; 2010 Feb; 12(1):13-22. PubMed ID: 20425480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ursodeoxycholic acid in chronic liver disease.
    de Caestecker JS; Jazrawi RP; Petroni ML; Northfield TC
    Gut; 1991 Sep; 32(9):1061-5. PubMed ID: 1916492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of cholestatic liver disease].
    Pleşa A
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
    Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
    Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children.
    Poupon R; Poupon RE
    Pharmacol Ther; 1995 Apr; 66(1):1-15. PubMed ID: 7630925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.
    Scher H; Bishop WP; McCray PB
    Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
    Mazzella G; Rizzo N; Azzaroli F; Simoni P; Bovicelli L; Miracolo A; Simonazzi G; Colecchia A; Nigro G; Mwangemi C; Festi D; Roda E
    Hepatology; 2001 Mar; 33(3):504-8. PubMed ID: 11230728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
    Qian JD; Yao TT; Wang Y; Wang GQ
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibrates and cholestasis.
    Ghonem NS; Assis DN; Boyer JL
    Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Guidelines for therapy of autoimmune liver disease.
    Ishibashi H; Komori A; Shimoda S; Gershwin ME
    Semin Liver Dis; 2007 May; 27(2):214-26. PubMed ID: 17520519
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Recent progress in the diagnosis and therapy of autoimmune hepatitis].
    Zenia M; Toda G
    Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1763-7. PubMed ID: 10581761
    [No Abstract]   [Full Text] [Related]  

  • 55. Choleretic effects of ursodeoxycholic acid on experimentally-induced intrahepatic cholestasis.
    Mizoguchi Y; Miyajima K; Kioka K; Seki S; Kobayashi K; Morisawa S
    Osaka City Med J; 1989 Nov; 35(2):83-91. PubMed ID: 2628845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
    Hay JE
    Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
    Silveira MG; Lindor KD
    Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Ursodeoxycholic acid: an alternative in the treatment of chronic cholestasis].
    Parés A; Rodés J
    Gastroenterol Hepatol; 1996 Feb; 19(2):58-67. PubMed ID: 8616682
    [No Abstract]   [Full Text] [Related]  

  • 59. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis.
    Bacq Y; Sentilhes L; Reyes HB; Glantz A; Kondrackiene J; Binder T; Nicastri PL; Locatelli A; Floreani A; Hernandez I; Di Martino V
    Gastroenterology; 2012 Dec; 143(6):1492-501. PubMed ID: 22892336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.